Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone917-289-1117
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Eyenovia (NASDAQ:EYEN) Frequently Asked Questions
What is Eyenovia's stock symbol?
Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."
How were Eyenovia's earnings last quarter?
Eyenovia Inc (NASDAQ:EYEN) announced its earnings results on Monday, August, 12th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. View Eyenovia's Earnings History.
When is Eyenovia's next earnings date?
What price target have analysts set for EYEN?
2 equities research analysts have issued twelve-month price objectives for Eyenovia's shares. Their predictions range from $9.00 to $14.00. On average, they anticipate Eyenovia's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 250.6% from the stock's current price. View Analyst Price Targets for Eyenovia.
What is the consensus analysts' recommendation for Eyenovia?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.
What are Wall Street analysts saying about Eyenovia stock?
Here are some recent quotes from research analysts about Eyenovia stock:
- 1. According to Zacks Investment Research, "Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York. " (8/16/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $240M, which includes a discounted cash flow-based asset value for all four micro-dosing products, with a 15% discount rate and 1% terminal growth rate. Probabilities of success assigned are 80%, 75%, 55% and 45% for MicroPine, respectively." (2/14/2019)
Has Eyenovia been receiving favorable news coverage?
Headlines about EYEN stock have been trending negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eyenovia earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Eyenovia.
Are investors shorting Eyenovia?
Eyenovia saw a increase in short interest in September. As of September 30th, there was short interest totalling 283,000 shares, an increase of 17.9% from the August 30th total of 240,100 shares. Based on an average trading volume of 130,800 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.9% of the company's shares are sold short. View Eyenovia's Current Options Chain.
Who are some of Eyenovia's key competitors?
Some companies that are related to Eyenovia include Galectin Therapeutics (GALT), Aeglea Bio Therapeutics (AGLE), Assembly Biosciences (ASMB), Albireo Pharma (ALBO), Mirum Pharmaceuticals (MIRM), Osmotica Pharmaceuticals (OSMT), Seres Therapeutics (MCRB), Xenon Pharmaceuticals (XENE), Constellation Pharmaceuticals (CNST), Xeris Pharmaceuticals (XERS), Kamada (KMDA), Athersys (ATHX), TapImmune (MRKR), LifeVantage (LFVN) and Spero Therapeutics (SPRO).
What other stocks do shareholders of Eyenovia own?
Who are Eyenovia's key executives?
Eyenovia's management team includes the folowing people:
- Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
- Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
- Mr. Luke Clauson, VP of R&D (Age 40)
- Mr. John P. Gandolfo, CFO & Sec. (Age 58)
- Mr. Michael M. Rowe, VP of Marketing
When did Eyenovia IPO?
(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.
How do I buy shares of Eyenovia?
Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Eyenovia's stock price today?
One share of EYEN stock can currently be purchased for approximately $3.28.
How big of a company is Eyenovia?
What is Eyenovia's official website?
How can I contact Eyenovia?
Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]
MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)
| Community Ranking: | | 2.3 out of 5 ( ) |
| Outperform Votes: | | 111 (Thanks for Voting!) |
| Underperform Votes: | | 135 (Thanks for Voting!) |
| Total Votes: | | 246 |
